Furthermore, recent advances in PRMT3‐targeted protein degradation tools have demonstrated enhanced specificity compared to traditional methods, presenting a promising direction for the development of more precise therapeutic strategies.[56] Applying these new tools in PS19, AD models, and related tauopathy animal models holds promise for advancing therapeutic strategies targeting tau pathology. The gene discussed is PRMT3; the disease is tauopathy.